

Category:2003 films Category:2000s thriller drama films Category:British films Category:British thriller drama films Category:English-language films Category:Crucifixion of Jesus in film Category:History of Nazareth Category:Films about Christianity Category:Films shot in Cyprus Category:Films set in Israel Category:Films based on the New Testament Category:British drama films Category:Christian drama films Category:2000s drama films Category:Films with screenplays by Frank Darabont Category:Films with screenplays by George Miller Category:Films scored by Carter Burwell Category:American drama films Category:American films Category:American thriller drama films and highlights the need for further in vivo studies on gene editing approaches in the PDX model. At this point, there is no direct evidence that ATP8A1 is a "bona fide" therapeutic target in PD. There are several caveats that need to be addressed in the current study. First, the transduction efficiency of lentiviral vectors in the current study is relatively low (~1%), and therefore, it may not be representative of the range of transduction efficiencies observed in human disease. Second, we only look at the acute effects of gene editing. Long-term gene editing approaches may lead to different phenotypes. Third, the overexpression of ATP8A1 in PDX is moderate (~10-fold higher than endogenous levels), and therefore, the PDX model used in this study is more comparable to cellular models than the human patients in whom therapeutic targets for PD are identified. In fact, the overexpression of ATP8A1 in the human genetic studies is more similar to the gene editing approach adopted in the current study. Finally, the PDX model used in this study is between ages of 1 and 2 months. More advanced PDX models, such as those between ages of 3 and 4 months, could better model progressive disease in patients. In summary, this study validates the use of PDX model to identify therapeutic targets of neurodegenerative diseases. The novel findings of this study include the demonstration of the feasibility of implementing the PDX model for therapeutic target validation studies and the identification of ATP8A1 as a potential therapeutic target for PD. Future studies need to address the safety and

[Download](#)

